Cite
HARVARD Citation
Engel, S. et al. (2019). Vemurafenib and cobimetinib combination therapy for BRAFV600E-mutated melanoma favors posterior reversible encephalopathy syndrome. Annals of oncology. pp. 1014-1016. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Engel, S. et al. (2019). Vemurafenib and cobimetinib combination therapy for BRAFV600E-mutated melanoma favors posterior reversible encephalopathy syndrome. Annals of oncology. pp. 1014-1016. [Online].